Your browser doesn't support javascript.
loading
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand, Philippe; Zinzani, Pier Luigi; Lee, Hun Ju; Johnson, Nathalie A; Brice, Pauline; Radford, John; Ribrag, Vincent; Molin, Daniel; Vassilakopoulos, Theodoros P; Tomita, Akihiro; von Tresckow, Bastian; Shipp, Margaret A; Herrera, Alex F; Lin, Jianxin; Kim, Eunhee; Chakraborty, Samhita; Marinello, Patricia; Moskowitz, Craig H.
Afiliação
  • Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Zinzani PL; Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Lee HJ; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
  • Johnson NA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Brice P; Department of Medicine, Jewish General Hospital, Montreal, QC, Canada.
  • Radford J; Hémato-Oncologie, Hôpital Saint-Louis, Paris, France.
  • Ribrag V; Department of Medical Oncology, NIHR Clinical Research Facility, the Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Molin D; Early Drug Department (DITEP), Gustave Roussy, Villejuif, France.
  • Vassilakopoulos TP; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Tomita A; Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • von Tresckow B; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Shipp MA; Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Herrera AF; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Lin J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Kim E; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
  • Chakraborty S; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ.
  • Marinello P; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ.
  • Moskowitz CH; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ.
Blood ; 142(10): 878-886, 2023 09 07.
Article em En | MEDLINE | ID: mdl-37319435
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2023 Tipo de documento: Article